Über diesen Podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
262 Folgen · science
BioSpace
Neueste FolgeThe supply chain fault lines of modern pharma
Über diesen Podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Neue Folgen
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9. Sept. · 20 Min.
- Breaking borders: Building biotech scale in Benelux3. Sept. · 19 Min.
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals2. Sept. · 20 Min.
- Fragile X at a turning point: Breaking through the clinical bottleneck27. Aug. · 19 Min.
- Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed26. Aug. · 23 Min.
- Rewriting the rules of CMV prevention20. Aug. · 20 Min.
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more19. Aug. · 19 Min.
- The Italian inflection point: Clinical strength, culture and capital13. Aug. · 19 Min.
- Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight12. Aug. · 19 Min.
- Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms11. Aug. · 23 Min.
podlinkr.com/de/biospace
Für ein Plakat oder eine Folie.